Navigation Links
Antibiotic May Help Ease Irritable Bowel

By Jenifer Goodwin
HealthDay Reporter

WEDNESDAY, Jan. 5 (HealthDay News) -- A two-week course of an antibiotic relieved bloating and other symptoms of irritable bowel syndrome, a common gastrointestinal disorder, for more than two months after treatment ended, new research shows.

Researchers say the antibiotic, rifaximin, made by Salix Pharmaceuticals, is the first treatment for irritable bowel syndrome that gets at the underlying cause of the condition, rather than just treating the symptoms.

The findings are published in the Jan. 6 issue of the New England Journal of Medicine.

The research involved 1,260 people with irritable bowel syndrome (IBS) but no constipation. They took either rifaximin or a placebo three times a day for two weeks.

In the four weeks after treatment, nearly 41 percent of those who'd taken rifaximin reported "adequate relief" of IBS symptoms, compared with about 32 percent of the placebo group.

When asked about bloating, about 40 percent in the rifaximin group said they had found relief from this problem, compared with about 30 percent who'd taken the placebo. Bloating can be one of the most vexing aspects of IBS, gastroenterologists said.

People in the rifaximin group also reported less abdominal pain and loose or watery stools, and the effects of the antibiotic therapy persisted 10 weeks after treatment ended.

This is important, said Dr. Yehuda Ringel, a gastroenterologist and associate professor of medicine at the University of North Carolina at Chapel Hill and a study co-author.

Current treatments, including anti-diarrheal and anti-constipation medications, target only the symptoms of IBS and work only as long as people continue taking the drugs, Ringel said. But rifaximin may do more.

"This research shows that antibiotics work for patients with IBS, suggesting the intestinal microbiota has a role in causing this condition," Ringel said. "The effect lasted for 10 weeks after discontinuation of the medication, suggesting we are changing something in the underlying abnormality."

Salix Pharmaceuticals funded the research, a phase 3 clinical trial. The company has applied for U.S. Food and Drug Administration approval for the medication, which is currently approved for treating traveler's diarrhea and hepatic encephalopathy, a brain disorder caused by liver disease.

Another benefit of rifaximin, Ringel said, is that it's poorly absorbed by the body, meaning that it passes through the stomach into the intestines and is excreted in the stool instead of being absorbed into the bloodstream.

That means there's less risk for side effects than there is with antibiotics that are absorbed systemically, said Dr. Jan Tack, a professor of medicine and head of the Translational Research Center for Gastrointestinal Disorders at the University of Leuven in Belgium, who wrote an accompanying editorial.

"Rifaximin looks promising and has a number of attractive features," Tack said. "IBS is a very prevalent condition, and the number of therapies of proven efficacy is very very limited. There is clearly a need for new therapies."

As many as 20 percent of Americans have symptoms of IBS, a recurring condition that can include cramping, abdominal pain, bloating and a change in stool consistency and frequency, such as constipation and diarrhea, according to the U.S. National Digestive Diseases Information Clearinghouse.

Though uncomfortable and distressing, IBS does not harm the intestines and does not raise the risk for other diseases, such as cancer, Ringel said.

The cause of IBS is unknown. Researchers have not been able to determine a specific abnormality, such as an infection or inflammation, that explains it.

Dietary changes and stress reduction help many people. Doctors also sometimes suggest anti-diarrheal medications, medications to relieve bloating and constipation and, for persistent cases, antidepressants, which can help reduce the sensation of abdominal pain, Tack said.

But for some, nothing much works, and IBS can leave them unable to work, attend social events or even travel short distances.

Prior research has suggested that an imbalance in gut flora, or bacteria that live in the small intestine and colon, might contribute to IBS.

The fact that an antibiotic, which kills bacteria, was effective supports that, Ringel said.

But there is much still to learn. Experts don't know if an alteration of the microflora causes the condition or, perhaps, is a result of the condition, Ringel said.

And rifaximin is a broad-spectrum antibiotic, meaning it kills lots of types of bacteria, Tack said. Researchers also don't know which bacteria might contribute to IBS.

"And right now we only have 12 weeks of data," Tack said. "What happens if you relapse? Can you treat them again with rifaximin, and will it work?"

More information

The U.S. National Digestive Diseases Information Clearinghouse has more on irritable bowel syndrome.

SOURCES: Yehuda Ringel, M.D., associate professor, medicine, division of gastroenterology and hepatology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, N.C.; Jan Tack, M.D., Ph.D., professor, medicine, Translational Research Center for Gastrointestinal Disorders, University of Leuven, Leuven, Belgium; Jan. 6, 2011, New England Journal of Medicine

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Giant Eagle Pharmacy Free Antibiotics Program Surpasses $3 Million in Free Prescriptions
2. Poll: Hypothetical anthrax attack and antibiotics
3. Chitosan as alternative to growth-promoting antibiotics for ruminants
4. Penicillin Allergy Might Not Include Related Antibiotic
5. Hard to Treat Diseases (HTDS) Awarded Two Antibiotics Certificates For Chile
6. ID physicians call for 10 new antibiotics by 2020
7. Misinformation About Antibiotics Can Travel to Large Audience Via Twitter: Study
8. Misinformation about antibiotics can travel to large audience via Twitter: study
9. Researchers find compound effective in destroying antibiotic-resistant biofilms
10. Antibiotic regimen effective for reactive arthritis
11. Combination antibiotics effective against chlamydia-induced arthritis
Post Your Comments:
Related Image:
Antibiotic May Help Ease Irritable Bowel
(Date:11/27/2015)... ... November 27, 2015 , ... The men and ... nonprofit healthcare organizations in the country. They have overseen financial turnarounds, shown commitment ... advance the healthcare industry as a whole through their advocacy and professional efforts. ...
(Date:11/27/2015)... ... ... Indosoft Inc., developer and distributor of the world-class Asterisk ... Term Support) into its Q-Suite 5.10 product line. , Making the change to ... of Asterisk that will receive not only security fixes, but feature and bug ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... system for diagnostic imaging in the Waterloo region. Using the Ocean Platform, family ... tests directly from their electronic medical record (EMR) without the need for redundant ...
(Date:11/26/2015)... ... 2015 , ... Jobs in hospital medical laboratories and in the imaging field ... agency Aureus Medical Group . These fields, as well as travel ... for healthcare jobs through the company’s website, , The leading healthcare ...
(Date:11/26/2015)... , ... November 26, 2015 , ... ... set of retro-fused, self-animating trailer titles with ProTrailer: Vintage. This newly styled ProTrailer ... classically-influenced trailer titles work with any font, giving users limitless opportunities to stylize ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... 26, 2015 ... the "2016 Global Tumor Marker Testing ... and Sales Segment Forecasts, Innovative Technologies, Instrumentation ... to their offering. --> ... "2016 Global Tumor Marker Testing Market: ...
(Date:11/26/2015)... , November 26, 2015 ... new combination approach blends immunotherapy with Bremachlorin-photodynamic therapy for ... combination approach blends immunotherapy with Bremachlorin-photodynamic therapy for advanced ... combination approach blends immunotherapy with Bremachlorin-photodynamic therapy for advanced ... has found that immunotherapy can be efficiently combined ...
(Date:11/26/2015)... 2015 3D bioprinting market is ... a new report by Grand View Research Inc. Rising prevalence ... demands kidney transplantation is expected to boost the market growth, ... organ transplantation. --> 3D bioprinting market is ... a new report by Grand View Research Inc. Rising prevalence ...
Breaking Medicine Technology: